Valuation Step-Ups of Private Dealmakers
This month we look at step-ups in valuations of selected biotechs that both went public in 1996 and had received an equity investment from at least one pharmaceutical alliance partner before the IPO.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.